Tirzepatide,
does it really help with Noninferiority to dulaglutide for major cardiovascular events?
research showsThe grade is C. In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide was not worse than dulaglutide beyond the prespecified margin. In 13,165 modified-intention-to-treat participants, cardiovascular death, myocardial infarction, or stroke occurred in 801 (12.2%) versus 862 (13.1%), HR 0.92, 95.3% CI 0.83 to 1.01. The upper bound was below the 1.05 margin, P=0.003 for noninferiority, but superiority failed at P=0.09.
ads claimClaims that tirzepatide reduces cardiovascular events more than dulaglutide overstate a successful noninferiority result.
Useful facts when choosing a product
- Doses were tirzepatide up to 15 mg weekly and dulaglutide 1.5 mg weekly.
- The prespecified HR margin was 1.05, chosen to preserve at least half of dulaglutide's placebo-established effect.
- The sponsor funded, co-designed, oversaw, collected, and initially analyzed the trial; several authors were Eli Lilly employees.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.tirzepatide.UNK.noninferiority-to-dulaglutide-for-major-cardiovascular-events.noninferior.MULTIUnknown > Tirzepatide > Unknown > Noninferiority to dulaglutide for major cardiovascular events > Noninferiority claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
SURPASS-CVOT randomized 13,299 people at 640 sites in 30 countries and analyzed 13,165, 6,586 versus 6,579, after regulatory-requested exclusion of 134 patients. Median follow-up was 4.0 years and 1,663 primary events occurred. Eli Lilly funded the trial, co-designed it with the academic committee, oversaw conduct and monitoring, collected data, and performed the initial analysis. Monash statisticians then validated analyses, and an independent blinded committee adjudicated events. Verdict 751 is B with 79 points for weight, verdict 914 is C with 59 points for glycated hemoglobin, verdict 1061 is C with 59 points for sleep apnea, verdict 1075 is B with 77 points for obesity-associated HFpEF events, verdict 1162 is B with 76 points for diabetes prevention, and verdict 1638 is D with 24 points for a CagriSema comparison. In particular, verdict 1075 used a different HFpEF population and comparator; this verdict concerns dulaglutide in type 2 diabetes with ASCVD.
Why this is classified as C (56)
A large blinded hard-endpoint trial met noninferiority, but manufacturer-only evidence, noninferiority design, and absence of a per-protocol efficacy analysis cap it at C with 56 points.
Counterpoint. All-cause death was 8.6% versus 10.2%, HR 0.84, but this secondary result does not replace the failed primary superiority test.
Rejudgment record. Cross-check applied — SURPASS-CVOT primary paper cross-checked for margin, modified intention-to-treat population, superiority, funding, and adjudication
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Noninferiority to dulaglutide for MACE | C | The prespecified HR margin of 1.05 was met. |
| Superiority to dulaglutide for MACE | D | Superiority was not established, P=0.09. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Nicholls SJ et al. 2025 SURPASS-CVOT | Multinational double-blind active-controlled noninferiority trial with blinded independent adjudication | 13,299 randomized; 13,165 in modified intention-to-treat analysis, 6,586 versus 6,579 | Supported by Eli Lilly, which co-designed, oversaw, collected data, and performed the initial analysis | First cardiovascular death, myocardial infarction, or stroke | 801 (12.2%) versus 862 (13.1%), HR 0.92, 95.3% CI 0.83 to 1.01; noninferiority P=0.003; superiority P=0.09 | Decisive single manufacturer-funded trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-06).
Final verification and publication gate: Codex · Evidence date: 2026-08-06 · Corrections: none
Cite this verdict
[Chamgap] Tirzepatide x major cardiovascular events versus dulaglutide — Evidence Grade C·56. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/tirzepatide-versus-dulaglutide-major-cardiovascular-events/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.